Expanding fundamental knowledge about undifferentiated cells
with a focus on cancer and regenerative medicine

Cell Gitik Inc. is an early-stage privately-owned Canadian life sciences company based in Vancouver. The company is researching fundamental mechanisms that globally control the undifferentiated state of cells in many types of cancer and early mammalian embryos. We will then use that knowledge to develop a highly targeted and universal anti-cancer "differentiation therapy" and a next-generation technology for reprogramming somatic cells into clinical-grade induced pluripotent stem cells (iPSCs) for safer regenerative medicine.

Cell Gitik's mission has two parts: (1) to develop a radically new anti-cancer therapeutic approach to improve treatments for cancer patients and (2) to pioneer the development of a technology aimed at generating clinically safe adult tissue-derived pluripotent cells to advance regenerative therapies.

Cell Gitik Inc. is a scientific enterprise with social goals: it strives to fulfill its mission at a low cost and to achieve meaningful progress in the short term. We invite all interested parties to partner with us to accelerate efforts that address our mission.